CD43 Antibody [SPM503]

Product Specifications

Background

It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.

NCBI Gene ID

6693

Swiss Prot

P16150

Host

Mouse

Reactivity

Human

Immunogen

Myeloblastic KG1 cells were used as the immunogen for this CD43 antibody.

Clonality

Monoclonal

Clone

SPM503

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Immunology

Purification

Protein G affinity chromatography

Concentration

0.2 mg/mL

Buffer

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

Fragment

IgG1, kappa

Applications Notes

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes. 2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.